STAB

Statera Biopharma Inc. (STAB) | Rumor.io

Statera Biopharma

STAB

Attention (50-day avg)0%

Attention rank (50-day avg)#4,961

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0

Market capitalization7.1K

Earnings per share-2.36

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-101.9M

Social

What share of all stock conversation is about STAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Mar 16

Statera Biopharma, Inc. ($STAB) may see a price jump to $0.70 if they merge with Worksite Labs and achieve $50M in revenue.
The merger with Worksite Labs has not happened yet and may not occur, according to some opinions.
Statera Biopharma, Inc. ($STAB) has never had a stock split and may reach a $50M market cap if the merger with Worksite Labs is successful.

Generated by AI

Sentiment

Of the messages about STAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +14.03
Bearish	—	—	—	0% -14.03

Bullish· Oct 17

Statera Biopharma, Inc. ($STAB) has potential for growth, with some investors expecting it to reach $0.50-$0.75 or even $1.
The company's recent news, including Holobeam news, may have a positive impact on its stock price, potentially leading to a 30% increase.
Investors are optimistic about $STAB's future, with some expecting it to reach $5 and others believing it will "run hard" this week.

Bearish· Oct 7

The company's stock price may drop to as low as $0.03 due to its move to the OTC market.
The current price of $0.04 is considered a scam, and the stock is seen as overvalued compared to its true worth.
The stock's recent price drop is attributed to short sellers covering their positions, with 100,000 shares already being covered at a cost of 24.57% of the available stock.

Generated by AI

Topics

Of the messages about STAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	100%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Oct 6

Statera Biopharma, Inc. ($STAB) has completed its fiscal 2021 audit and filed its Form 10-K.
The company has been granted a European patent titled "Methods And Compositions For The Treatment Of Radiation-related Disorders".
Statera Biopharma is scheduled to have a hearing with the Nasdaq Hearings Panel on October 6 to address recent non-compliance due to filing delinquency.

Technical Analysis· Apr 28

$STAB needs to break through $0.41 resistance for a potential uptrend.
A break above $0.50 could lead to a parabolic move for $STAB.
The 200 SMA on the 3-minute chart is currently serving as support for $STAB.

Generated by AI

Community

Of the messages about STAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	81.82%
Newcomers	—	—	0%	18.18%

Regulars· Oct 21

The company Statera Biopharma, Inc. has filed its Form 10-Q with the SEC, indicating its quarterly financial report is now available.
Statera Biopharma has reached an agreement with Silverback Capital and AVOF, although the terms of the deal are not specified.
The stock's momentum is continuing, with a price increase of 13.8% and a short float of 1.1%, indicating a relatively low level of short selling.

Newcomers· Oct 21

Newcomers are focusing on the recent surge in Statera Biopharma's stock price, with some seeing a 50% increase in value.
There has been a significant event in the company's history, with Statera Biopharma filing a Form 10-Q and reaching an agreement with Silverback Capital and AVOF.
The stock's price is currently being impacted by a wide spread, making it difficult for some to enter trades, but there are opportunities for entry at certain price levels.

Generated by AI

Also Discussed

Investors talking about STAB also mention

#	Name	Attention
1	Adaptive Biotechnologies Corporation Common StockADPT	0%new
2	China Auto Logistics Inc.CALI	0.06%-0.49
3	Gyre Therapeutics Inc.GYRE	0%0
4	CareCloud Inc.CCLD	0%new
5	Nanoviricides Inc.NNVC	0%0
6	T Stamp Inc. Class A Common StockIDAI	0%new
7	PFIN - P&F Industries, Inc.	——
8	GLG - TD Holdings, Inc.	——
9	Akari Therapeutics Plc ADRAKTX	0%0
10	Lee Enterprises, IncorporatedLEE	0%0

Statera Biopharma Inc.

Healthcare
Biotechnology

Statera Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies aimed at restoring immune balance and homeostasis. Its core focus is on creating novel treatments for conditions where the immune system plays a critical role, such as autoimmune disorders, neutropenia, anemia, emerging viral infections, and various cancers. Utilizing its proprietary Advanced Immunomodulating Multi-Component System (AIMS) platform, Statera Biopharma integrates diverse pharmacological factors including potency, selectivity, and pharmacokinetic-pharmacodynamic relationships to engineer its therapies. The company’s portfolio features late-stage candidates, with products in development for indications like Crohn's disease, hematological conditions, and inflammatory diseases. Additionally, Statera’s pipeline incorporates toll-like receptor (TLR) agonists and antagonists designed to modulate immune responses. Through these efforts, Statera Biopharma seeks to establish a new paradigm in immunotherapy by addressing complex diseases with comprehensive and safety-focused drug profiles, positioning itself within the biotechnology and pharmaceutical research sectors as an innovator in immune system modulation.

Website

Location

4333 Corbett Drive,

Fort Collins, CO, 80525

United States

Social

What share of all stock conversation is about STAB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Mar 16

Statera Biopharma, Inc. ($STAB) may see a price jump to $0.70 if they merge with Worksite Labs and achieve $50M in revenue.
The merger with Worksite Labs has not happened yet and may not occur, according to some opinions.
Statera Biopharma, Inc. ($STAB) has never had a stock split and may reach a $50M market cap if the merger with Worksite Labs is successful.

Generated by AI

Sentiment

Of the messages about STAB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +14.03
Bearish	—	—	—	0% -14.03

Bullish· Oct 17

Statera Biopharma, Inc. ($STAB) has potential for growth, with some investors expecting it to reach $0.50-$0.75 or even $1.
The company's recent news, including Holobeam news, may have a positive impact on its stock price, potentially leading to a 30% increase.
Investors are optimistic about $STAB's future, with some expecting it to reach $5 and others believing it will "run hard" this week.

Bearish· Oct 7

The company's stock price may drop to as low as $0.03 due to its move to the OTC market.
The current price of $0.04 is considered a scam, and the stock is seen as overvalued compared to its true worth.
The stock's recent price drop is attributed to short sellers covering their positions, with 100,000 shares already being covered at a cost of 24.57% of the available stock.

Generated by AI

Topics

Of the messages about STAB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	100%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Oct 6

Statera Biopharma, Inc. ($STAB) has completed its fiscal 2021 audit and filed its Form 10-K.
The company has been granted a European patent titled "Methods And Compositions For The Treatment Of Radiation-related Disorders".
Statera Biopharma is scheduled to have a hearing with the Nasdaq Hearings Panel on October 6 to address recent non-compliance due to filing delinquency.

Technical Analysis· Apr 28

$STAB needs to break through $0.41 resistance for a potential uptrend.
A break above $0.50 could lead to a parabolic move for $STAB.
The 200 SMA on the 3-minute chart is currently serving as support for $STAB.

Generated by AI

Community

Of the messages about STAB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	81.82%
Newcomers	—	—	0%	18.18%

Regulars· Oct 21

The company Statera Biopharma, Inc. has filed its Form 10-Q with the SEC, indicating its quarterly financial report is now available.
Statera Biopharma has reached an agreement with Silverback Capital and AVOF, although the terms of the deal are not specified.
The stock's momentum is continuing, with a price increase of 13.8% and a short float of 1.1%, indicating a relatively low level of short selling.

Newcomers· Oct 21

Newcomers are focusing on the recent surge in Statera Biopharma's stock price, with some seeing a 50% increase in value.
There has been a significant event in the company's history, with Statera Biopharma filing a Form 10-Q and reaching an agreement with Silverback Capital and AVOF.
The stock's price is currently being impacted by a wide spread, making it difficult for some to enter trades, but there are opportunities for entry at certain price levels.

Generated by AI

Statera Biopharma

Social

Mar 16

Sentiment

Bullish· Oct 17

Bearish· Oct 7

Topics

Announcements· Oct 6

Technical Analysis· Apr 28

Community

Regulars· Oct 21

Newcomers· Oct 21

News

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Also Discussed

Statera Biopharma Inc.

Company Information

Location

News

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Also Discussed

Social

Mar 16

Sentiment

Bullish· Oct 17

Bearish· Oct 7

Topics

Announcements· Oct 6

Technical Analysis· Apr 28

Community

Regulars· Oct 21

Newcomers· Oct 21